EIF2AK3 and metabolic syndrome: In vivo studies in mice demonstrated that dietary supplementation of TMAO increased phosphorylation of PERK and increased expression of the transcription factor Foxo1, a key driver of metabolic syndrome, readouts which were blocked by co-administration of the PERK inhibitor GSK2656157 or liver-specific knock-out of PERK.